Morgan Stanley’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-37,795
| Closed | -$31.2K | – | 8200 |
|
|
2025
Q1 | $31.2K | Hold |
37,795
| – | – | ﹤0.01% | 6424 |
|
|
2024
Q4 | $35.9K | Hold |
37,795
| – | – | ﹤0.01% | 6389 |
|
|
2024
Q3 | $37.8K | Sell |
37,795
-42
| -0.1% | -$47 | ﹤0.01% | 6292 |
|
|
2024
Q2 | $46.9K | Hold |
37,837
| – | – | ﹤0.01% | 6198 |
|
|
2024
Q1 | $49.2K | Sell |
37,837
-700
| -2% | -$798 | ﹤0.01% | 6218 |
|
|
2023
Q4 | $48.2K | Sell |
38,537
-4,157
| -10% | -$4.6K | ﹤0.01% | 6176 |
|
|
2023
Q3 | $55.5K | Sell |
42,694
-52,394
| -55% | -$84.7K | ﹤0.01% | 6123 |
|
|
2023
Q2 | $164K | Sell |
95,088
-417,011
| -81% | -$662K | ﹤0.01% | 5730 |
|
|
2023
Q1 | $748K | Buy |
512,099
+52,432
| +11% | +$101K | ﹤0.01% | 5031 |
|
|
2022
Q4 | $745K | Buy |
459,667
+214,017
| +87% | +$493K | ﹤0.01% | 5032 |
|
|
2022
Q3 | $822K | Buy |
245,650
+31,854
| +15% | +$144K | ﹤0.01% | 4995 |
|
|
2022
Q2 | $778K | Buy |
213,796
+5,807
| +3% | +$26.3K | ﹤0.01% | 5177 |
|
|
2022
Q1 | $1.5M | Buy |
207,989
+6,827
| +3% | +$58.2K | ﹤0.01% | 4722 |
|
|
2021
Q4 | $2.73M | Buy |
201,162
+65,522
| +48% | +$1.03M | ﹤0.01% | 4322 |
|
|
2021
Q3 | $2.84M | Sell |
135,640
-36,733
| -21% | -$789K | ﹤0.01% | 4279 |
|
|
2021
Q2 | $4.13M | Buy |
172,373
+70,593
| +69% | +$1.79M | ﹤0.01% | 3981 |
|
|
2021
Q1 | $2.98M | Sell |
101,780
-10,032
| -9% | -$294K | ﹤0.01% | 3933 |
|
|
2020
Q4 | $3.34M | Buy |
+111,812
| New | +$3.51M | ﹤0.01% | 3700 |
|
Morgan Stanley's KRON Position: Q2 2025 in Review
Morgan Stanley sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 37,795 shares — an estimated $31.2K sold.
Morgan Stanley first reported a position in KRON in Q4 2020 and held it in 18 quarters. The position peaked at $4.13M in Q2 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Morgan Stanley reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Morgan Stanley sold 37,795 Kronos Bio shares in Q2 2025, an estimated $31.2K.
- Morgan Stanley first reported a position in Kronos Bio in Q4 2020 and held it in 18 quarters.
- Morgan Stanley's Kronos Bio position peaked at $4.13M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.